Bioluminescent imaging of HPV-positive oral tumor growth and its response to image-guided radiotherapy

Cancer Research

Volumn 74, Issue 7, 2014, Pages 2073-2081

  Zhong, Rong ^a   Pytynia, Matt ^a   Pelizzari, Charles ^a   Spiotto, Michael ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; LUCIFERASE; MINICHROMOSOME MAINTENANCE PROTEIN 7; PROTEIN E6; PROTEIN E7; PROTEIN P16; RAPAMYCIN; TAMOXIFEN; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CONTROLLED STUDY; E6 GENE; E7 GENE; ENZYME ACTIVATION; EPITHELIUM CELL; IMAGE GUIDED RADIOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MOUTH INFECTION; MOUTH TUMOR; NONHUMAN; ONCOGENE K RAS; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR GROWTH;

ANIMALS; DISEASE MODELS, ANIMAL; INTEGRASES; LUCIFERASES; LUMINESCENT MEASUREMENTS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOUTH NEOPLASMS; PAPILLOMAVIRIDAE; RADIOTHERAPY, IMAGE-GUIDED;

EID: 84897397958     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2993     Document Type: Article

References (50)

1. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011;333:1154-7.
2. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333:1157-60.
3. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer 2011;11:9-22.
4. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35.
5. Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007;357:2552-61.
6. Kanojia D, Vaidya MM. 4-nitroquinoline-1-oxide induced experimental oral carcinogenesis. Oral Oncol 2006;42:655-67.
7. Shin MK, Pitot HC, Lambert PF. Pocket proteins suppress head and neck cancer. Cancer Res 2012;72:1280-9.
8. Caulin C, Nguyen T, Longley MA, Zhou Z, Wang XJ, Roop DR. Inducible activation of oncogenic K-ras results in tumor formation in the oral cavity. Cancer Res 2004;64:5054-8.
9. Raimondi AR, Molinolo A, Gutkind JS. Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model. Cancer Res 2009;69:4159-66.
10. Bian Y, Hall B, Sun ZJ, Molinolo A, Chen W, Gutkind JS, et al. Loss of TGF-beta signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation. Oncogene 2012;31:3322-32.
11. Bornstein S, White R, Malkoski S, Oka M, Han G, Cleaver T, et al. Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation. J Clin Invest 2009; 119:3408-19.
12. Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M, et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 2003;33:416-21.
13. Caulin C, Nguyen T, Lang GA, Goepfert TM, Brinkley BR, CaiWW, et al. An inducible mouse model for skin cancer reveals distinct roles for gainand loss-of-function p53 mutations. J Clin Invest 2007;117:1893-901.
14. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010;10:550-60.
15. Kimple RJ, Harari PM, Torres AD, Yang RZ, Soriano BJ, Yu M, et al. Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts. Clin Cancer Res 2013;19:855-64.
16. Yaromina A, Kroeber T, Meinzer A, Boeke S, Thames H, Baumann M, et al. Exploratory study of the prognostic value of microenvironmental parameters during fractionated irradiation in human squamous cell carcinoma xenografts. Int J Radiat Oncol Biol Phys 2011;80:1205-13.
17. Bray D, Yu SZ, Koprowski H II, Rhee J, Kumar S, Pericle F, et al. Combination nonviral interleukin 2 gene therapy and external-beam radiation therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg 2003;129:618-22.
18. Spiotto MT, Banh A, Papandreou I, Cao H, Galvez MG, Gurtner GC, et al. Imaging the unfolded protein response in primary tumors reveals microenvironments with metabolic variations that predict tumor growth. Cancer Res 2010;70:78-88.
19. Strati K, Pitot HC, Lambert PF. Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Natl Acad Sci U S A 2006;103:14152-7.
20. Munger K, Phelps WC, Bubb V, HowleyPM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989;63:4417-21.
21. Matsuda T, Cepko CL. Electroporation and RNA interference in the rodent retina in vivo and in vitro. Proc Natl Acad Sci U S A 2004; 101:16-22.
22. Vasioukhin V, Degenstein L, Wise B, Fuchs E. The magical touch: genome targeting in epidermal stem cells induced by tamoxifen application to mouse skin. Proc Natl Acad Sci U S A 1999;96:8551-6.
23. Chu KP, Le QT. Intensity-modulated and image-guided radiation therapy for head and neck cancers. Front Radiat Ther Oncol 2011;43: 217-54.
24. Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, et al. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 2001;61:6500-10.
25. Mishima K, Yamada E, Masui K, Shimokawara T, Takayama K, Sugimura M, et al. Overexpression of the ERK/MAP kinases in oral squamous cell carcinoma. Mod Pathol 1998;11:886-91.
26. Branca M, Ciotti M, Santini D, Bonito LD, Benedetto A, Giorgi C, et al. Activation of the ERK/MAP kinase pathway in cervical intraepithelial neoplasia is related to grade of the lesion but not to high-risk human papillomavirus, virus clearance, or prognosis in cervical cancer. Am J Clin Pathol 2004;122:902-11.
27. Landro ME, Dalbert D, Picconi MA, Cuneo N, Gonzalez J, Vornetti S, et al. Human papillomavirus and mutated H-ras oncogene in cervical carcinomas and pathological negative pelvic lymph nodes: a retrospective follow-up. J Med Virol. 2008;80:694-701.
28. Wentzensen N, Vinokurova S, von Knebel Doeberitz M. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res 2004;64:3878-84.
29. Schreiber K, Cannon RE, Karrison T, Beck-Engeser G, Huo D, Tennant RW, et al. Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors. Oncogene 2004;23:3972-9.
30. Jabbar SF, Abrams L, Glick A, Lambert PF. Persistence of high-grade cervical dysplasia and cervical cancer requires the continuous expression of the human papillomavirus type 16 E7 oncogene. Cancer Res 2009;69:4407-14.
31. Diamond I, Owolabi T, Marco M, Lam C, Glick A. Conditional gene expression in the epidermis of transgenic mice using the tetracyclineregulated transactivators tTA and rTA linked to the keratin 5 promoter. J Invest Dermatol 2000;115:788-94.
32. Tarutani M, Cai T, Dajee M, Khavari PA. Inducible activation of Ras and Raf in adult epidermis. Cancer Res 2003;63:319-23.
33. Yoshida S, Kajitani N, Satsuka A, Nakamura H, Sakai H. Ras modifies proliferation and invasiveness of cells expressing human papillomavirus oncoproteins. J Virol 2008;82:8820-7.
34. Arbeit JM, Munger K, Howley PM, Hanahan D. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J Virol 1994;68:4358-68.
35. Carraresi L, Tripodi SA, Mulder LC, Bertini S, Nuti S, Schuerfeld K, et al. Thymic hyperplasia and lung carcinomas in a line of mice transgenic for keratin 5-driven HPV16 E6/E7 oncogenes. Oncogene 2001;20: 8148-53.
36. Auewarakul P, Gissmann L, Cid-Arregui A. Targeted expression of the E6 and E7 oncogenes of human papillomavirus type 16 in the epidermis of transgenic mice elicits generalized epidermal hyperplasia involving autocrine factors. Mol Cell Biol 1994;14:8250-8.
37. Lambert PF, Pan H, Pitot HC, Liem A, Jackson M, Griep AE. Epidermal cancer associated with expression of human papillomavirus type 16 E6 and E7 oncogenes in the skin of transgenic mice. Proc Natl Acad Sci U S A 1993;90:5583-7.
38. Doan T, Herd K, Street M, Bryson G, Fernando G, Lambert P, et al. Human papillomavirus type 16 E7 oncoprotein expressed in peripheral epithelium tolerizes E7-directed cytotoxic T-lymphocyte precursors restricted through human (and mouse) major histocompatibility complex class I alleles. J Virol 1999;73:6166-70.
39. Henson B, Li F, Coatney DD, Carey TE, Mitra RS, Kirkwood KL, et al. An orthotopic floor-of-mouth model for locoregional growth and spread of human squamous cell carcinoma. J Oral Pathol Med 2007;36:363-70.
40. Kim SA, Kim YC, Kim SW, Lee SH, Min JJ, Ahn SG, et al. Antitumor activity of novel indirubin derivatives in rat tumor model. Clin Cancer Res 2007;13:253-9.
41. Liao CP, Zhong C, Saribekyan G, Bading J, Park R, Conti PS, et al. Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res 2007;67:7525-33.
42. Zhang N, Lyons S, Lim E, Lassota P. A spontaneous acinar cell carcinoma model for monitoring progression of pancreatic lesions and response to treatment through noninvasive bioluminescence imaging. Clin Cancer Res 2009;15:4915-24.
43. Scotto L, Kruithof-de Julio M, Paoluzzi L, Kalac M, Marchi E, Buitrago JB, et al. Development and characterization of a novel CD19Cherry-Luciferase (CD19CL) transgenic mouse for the preclinical study of Bcell lymphomas. Clin Cancer Res 2012;18:3803-11.
44. Hsieh CL, Xie Z, Yu J, Martin WD, DattaMW,WuGJ, et al. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model. Prostate 2007;67:685-91.
45. Squarize CH, Castilho RM, Abrahao AC, Molinolo A, Lingen MW, Gutkind JS. PTEN deficiency contributes to the development and progression of head and neck cancer. Neoplasia 2013;15:461-71.
46. Verhaegen F, Granton P, Tryggestad E. Small animal radiPeriodicalapy research platforms. Phys Med Biol 2011;56:R55-83.
47. Wong J, Armour E, Kazanzides P, Iordachita I, Tryggestad E, Deng H, et al. High-resolution, small animal radiation research platform with xray tomographic guidance capabilities. Int J Radiat Oncol Biol Phys 2008;71:1591-9.
48. Cuneo KC, Mito JK, Javid MP, Ferrer JM, Kim Y, Lee WD, et al. Imaging primary mouse sarcomas after radiation therapy using Cathepsin-Activatable fluorescent imaging agents. Int J Radiat Oncol Biol Phys 2013;86:136-42.
49. Moding EJ, Clark DP, Qi Y, Li Y, Ma Y, Ghaghada K, et al. Dual-energy micro-computed tomography imaging of radiation-induced vascular changes in primary mouse sarcomas. Int J Radiat Oncol Biol Phys 2013;85:1353-9.
50. Perez BA, Ghafoori AP, Lee CL, Johnston SM, Li Y, Moroshek JG, et al. Assessing the radiation response of lung cancer with different gene mutations using genetically engineered mice. Front Oncol 2013;3:72.